No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 10,105 | 9,422 | 16,126 | 20,648 | 18,899 | 22,359 | 22,269 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 3,338 | 2,693 | 3,466 | 4,192 | 3,230 | 4,053 | 4,437 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Vinati Organics Limited, established in Mumbai, India in 1989, operates as a specialty chemical enterprise specializing in the production and global distribution of organic intermediaries and monomers. While primarily serving the Indian market, the company also exports its diverse product range to key international regions including the United States, Europe, and various parts of Asia. Its extensive portfolio features a variety of specialty monomers, such as 2-acrylamido-2-methylpropane sulphonic acid (2-AMPS) and its sodium salt, alongside N-tertiary butyl acrylamide (NTBA) and N-tertiary octyl acrylamide (NTOA). The company is also a significant producer of aromatic compounds. These include isobutyl benzene, a critical precursor for manufacturing ibuprofen, an anti-inflammatory analgesic drug; normal butyl benzene, utilized in the synthesis of numerous chemical intermediates; and hexenes, valued for applications like low-boiling point solvents, thinners, extraction agents, tire retreading, as octane boosters for gasoline, and in C5/C6 aliphatic petroleum. Butyl phenols are also part of this segment. Further expanding its chemical offerings, Vinati Organics provides methyl-4-tert butyl benzoate and para tertiary butyl benzoic acid. It manufactures isobutylene, a branched olefin; methanol, which functions as a chemical intermediate; and high-purity methyl tertiary butyl ether (MTBE), widely used as a solvent in organic and pharmaceutical synthesis, as well as in Grignard's reagent production. Tertiary-butylamine is another specialized chemical produced. Additionally, the firm develops polymers tailored for diverse industrial sectors, including construction, ceramics, oil drilling, mining, leather processing, and paper manufacturing.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Vinati Organics Limited (VINATIORGA.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Vinati Organics Limited, established in Mumbai, India in 1989, operates as a specialty chemical enterprise specializing in the production and global distribution of organic intermediaries and monomers. While primarily serving the Indian market, the company also exports its diverse product range to key international regions including the United States, Europe, and various parts of Asia. Its extensive portfolio features a variety of specialty monomers, such as 2-acrylamido-2-methylpropane sulphonic acid (2-AMPS) and its sodium salt, alongside N-tertiary butyl acrylamide (NTBA) and N-tertiary octyl acrylamide (NTOA). The company is also a significant producer of aromatic compounds. These include isobutyl benzene, a critical precursor for manufacturing ibuprofen, an anti-inflammatory analgesic drug; normal butyl benzene, utilized in the synthesis of numerous chemical intermediates; and hexenes, valued for applications like low-boiling point solvents, thinners, extraction agents, tire retreading, as octane boosters for gasoline, and in C5/C6 aliphatic petroleum. Butyl phenols are also part of this segment. Further expanding its chemical offerings, Vinati Organics provides methyl-4-tert butyl benzoate and para tertiary butyl benzoic acid. It manufactures isobutylene, a branched olefin; methanol, which functions as a chemical intermediate; and high-purity methyl tertiary butyl ether (MTBE), widely used as a solvent in organic and pharmaceutical synthesis, as well as in Grignard's reagent production. Tertiary-butylamine is another specialized chemical produced. Additionally, the firm develops polymers tailored for diverse industrial sectors, including construction, ceramics, oil drilling, mining, leather processing, and paper manufacturing.
